G1 Therapeutics

G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. Its products pipeline includes trilaciclib, rintodestrant, and lerociclib. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

G1 Therapeutics excels in Q4 with Cosela sales surge and optimistic 2023 outlook

G1 Therapeutics delivered strong financial results in Q4 2022, driven by the impressive performance of Cosela in the small cell lung cancer market. Despite organizational changes to conserve capital, the company remains focused on growth and innovation. With a solid cash balance projection for 2023 and a growing customer base, G1 Therapeutics is poised for continued success.

G1 Therapeutics reports robust Q1 performance and optimistic growth outlook

G1 Therapeutics demonstrated strong financial performance and commercial growth in Q1 2023, with COSELA showing promising results and a positive outlook for the future.
While facing challenges related to potential drug interactions, the company is well-positioned to capitalize on opportunities through upcoming data readouts and strategic decisions.
Investors can be optimistic about G1 Therapeutics' continued progress, supported by a solid financial foundation and a focus on maximizing COSELA's potential.

G1 Therapeutics reports resilient Q2 performance amidst challenges and opportunities

G1 Therapeutics delivered a strong financial performance in Q2 2023, showcasing resilience and strategic financial management amidst challenges.
The company's focus on advancing its clinical pipeline and securing survival results in early 2024 positions it for future growth and value creation.
While facing challenges such as a chemotherapy shortage and operational efficiency, G1 Therapeutics maintains stability and confidence in its financial outlook.
Opportunities lie in capitalizing on COSELA sales growth, advancing clinical programs, and leveraging financial flexibility for sustained growth and innovation.

G1 Therapeutics overcomes supply challenges, eyes growth in oncology

G1 Therapeutics exhibited resilience in revenue growth despite challenges with COSELA's market supply, showcasing operational strength.
The company's strong financial position and cost management efforts bode well for sustainable growth and value creation.
Exciting opportunities in clinical trials and market expansion present avenues for future success and competitive positioning in the oncology sector.

G1 Therapeutics excels in Q4 2023, poised for growth ahead

G1 Therapeutics demonstrated strong performance in Q4 2023 with notable revenue growth and expense management.
COSELA's market share and promising trial results highlight strengths in the product portfolio.
While challenges like trial result anticipation and cost efficiency persist, opportunities for growth and optimization are evident.
Overall, G1 Therapeutics shows promise with a healthy cash position and positive sales guidance for 2024.

G1 Therapeutics reports strong Q1 earnings and diversifies revenue streams

G1 Therapeutics delivered robust financial results, showcasing growth in revenue and cost management improvements in Q1 2024.
While facing challenges in managing expenses and advancing clinical trials, the company remains optimistic about revenue guidance and market opportunities.
With a solid cash position and strategic partnerships, G1 Therapeutics is well-positioned to drive future growth and innovation in the oncology sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

G1 Therapeutics, Inc. is a commercial-stage oncology firm focused on the research and marketing of next-generation anticancer treatments.

SAN FRANCISCO and RESEARCH TRIANGLE PARK, N.C., Jan.  14, 2020  (GLOBE NEWSWIRE) -- Quantum Leap Healthcare Collaborative™ (QLHC) and G1 Therapeutics, Inc. (Nasdaq:  GTHX ) announced today a collaboration to evaluate trilaciclib, an investigational therapy designed to improve outcomes for people with cancer treated with chemotherapy, in a new randomized, investigational treatment arm for the ongoing I-SPY 2 TRIAL™ for neoadjuvant treatment of locally advanced breast cancer.

Quantum Leap Healthcare Collaborative and G1 Therapeutics Announce the Selection of Trilaciclib in the I-SPY 2 TRIAL for Breast Cancer

RESEARCH TRIANGLE PARK, N.C. and SAN ANTONIO, Dec.  11, 2019  (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:  GTHX ), a clinical-stage oncology company, today reported additional data from the Phase 1b/2a clinical trial investigating its oral CDK4/6 inhibitor lerociclib in combination with fulvestrant for the treatment of estrogen receptor-positive, HER2-negative (ER+, HER2-) breast cancer. Updated findings presented during a poster session ( P1-19-17 ) at the 2019 San Antonio Breast Cancer Symposium (SABCS) showed lerociclib, dosed without a drug holiday, has a differentiated safety and tolerability profile than observed in clinical trials with currently marketed CDK4/6 inhibitors. Preliminary efficacy findings were consistent with other CDK4/6 inhibitors used in combination with fulvestrant.

G1 Therapeutics Presents Updated Data from Phase 1b/2a Trial of Oral CDK4/6 Inhibitor Lerociclib at 2019 San Antonio Breast Cancer Symposium (SABCS)

ACADIA Pharma

Alector Inc

Amarin Corporation Plc

Avadel Pharma

Bausch Health Companies Inc

Biogen

Epizyme

MacroGenics

Syros Pharmaceuticals

Companies in the biotech and pharmaceutical industries are subject to a sizable amount of risk with regards to their drug candidates passing clinical trials and gaining regulatory approval.

Major Biopharma Catalysts on the December FDA Calendar

RESEARCH TRIANGLE PARK, N.C., Nov.  26, 2019  (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca, M.D., Ph.D. will participate in a fireside chat at the Evercore ISI 2nd Annual HealthCONx Conference.  The fireside chat will take place on Wednesday, December 4, 2019 at 4:35 p.m. at the Boston Four Seasons Hotel in Boston, MA.

G1 Therapeutics to Participate in Evercore ISI 2nd Annual HealthCONx Conference on December 4, 2019

G1 Therapeutics, Inc. (GTHX) CEO Mark Velleca on Q3 2019 Results - Earnings Call Transcript

RESEARCH TRIANGLE PARK, N.C., Oct.  29, 2019  (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host a webcast and conference call to provide a corporate and financial update for the third quarter of 2019 on Tuesday, November 5, 2019 at 4:30 p.m. ET.

G1 Therapeutics to Provide Third Quarter Corporate and Financial Update on November 5, 2019

Regeneron Pharmaceuticals

Kiniksa Pharmaceuticals Ltd

Some investors think the market's been too hard on these drugmakers.

Are These 3 Beaten-Down Biotech Stocks Bargains Now?

After soaring almost 70% year to date, G1 shares were under pressure following new data on two drug candidates.

Why G1 Therapeutics Stock Plunged 37.2% in September

Cal-Maine Foods

Teekay

Tough going kept these stocks from joining the rally.

Why Cal-Maine Foods, G1 Therapeutics, and Teekay LNG Partners Slumped Today

-- Company to host investor and analyst event, webcast and conference call today  at 12:45 p.m. ET --  RESEARCH TRIANGLE PARK, N.C. and BARCELONA, SPAIN, Sept.  29, 2019  (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:  GTHX ), a clinical-stage oncology company, today announced preliminary results from a Phase 1/2a dose-escalation study of G1T48, an oral selective estrogen receptor degrader (SERD), in patients with estrogen receptor-positive, HER2-negative (ER+, HER2-) breast cancer. In the trial, G1T48 was well tolerated and demonstrated evidence of anti-tumor activity in heavily pre-treated patients. These data were presented as part of a poster session ( 340P ) at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain.

G1 Therapeutics Presents First Clinical Data on Oral SERD G1T48 Demonstrating Safety and Tolerability in Patients with Advanced Breast Cancer at ESMO 2019

-- Trial results published simultaneously in The Lancet Oncology --    -- Company also to present updated Phase 2 results demonstrating myelopreservation benefits in small cell lung cancer (SCLC) patients receiving trilaciclib and chemotherapy in combination with Tecentriq® --

G1 Therapeutics Presents Updated Data at ESMO 2019 from Randomized Phase 2 Trial of Trilaciclib in Combination with Chemotherapy in Metastatic Triple-Negative Breast Cancer Demonstrating Significant Improvement in Overall Survival

GTHX has lead drug trilaciclib as a myelopreservation agent supporting chemo regimens.

G1 Therapeutics: An Excellent Opportunity In A Underserved Space

-  Company to present first clinical data on oral SERD G1T48 in breast cancer -

G1 Therapeutics to Present New Clinical Data Across Pipeline at European Society for Medical Oncology (ESMO) 2019 Congress

RESEARCH TRIANGLE PARK, N.C., Sept.  03, 2019  (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Financial Officer Jennifer Moses will present a company overview at the H.C. Wainwright Annual Global Investment Conference.  The presentation will take place on Monday, September 9, 2019 at 9:35 a.m. at the Lotte New York Palace Hotel in New York, NY.

G1 Therapeutics to Present at H.C. Wainwright Annual Global Investment Conference on September 9, 2019

G1 Therapeutics, Inc. (GTHX) CEO Mark Velleca on Q2 2019 Results - Earnings Call Transcript

Trilaciclib is targeting a huge underserved market opportunity.

G1 Therapeutics Looks Forward To Myelopreservation Opportunity In 2019

CEL-SCI

Pfizer

These stocks were huge winners last week. But can their momentum continue?

These 3 Biotech Stocks Skyrocketed Last Week -- Are They Buys Now?

Iovance Biotherapeutics

Nektar Therapeutics

Three biotechs, along with recent IPO Pinterest (PINS), are among our four charts to watch today.

3 Biotechs On the Move

Snap

SunPower

Favorable comments from analysts helped some of these power players stand out on a strong day for the market.

Why SunPower, Snap, and G1 Therapeutics Jumped Today

Shares of G1 Therapeutics Inc. were advancing strongly on above-average volume Tuesday in reaction to a clinical trial readout.

What's Behind The Rally In Small-Cap Biotech G1 Therapeutics?

CytomX Therapeutics

Five Prime Therapeutics

Mersana Therapeutics

The 55th annual meeting of the American Society of Clinical Oncology (ASCO) has just concluded, and there were some significant moves we saw as a result.

ASCO Winners That Could Still More Than Double

G1 Therapeutics, Inc. (GTHX) CEO Mark Velleca on Q1 2019 Results - Earnings Call Transcript

G1 Therapeutics announced that it had a productive end of phase 2 meeting with the FDA for trilaciclib as a myelopreservation agent for patients with small cell lung cancer.

G1 Therapeutics Looks To Regulatory Agency For Its Bone Marrow Preservation Drug

The clinical-stage biopharmaceutical company is on track to file for FDA approval of its first drug, trilaciclib.

Why G1 Therapeutics Is Soaring 16% Today

Shares of G1 Therapeutics Inc, an oncology biotech, have climbed to their highest level so far in 2019, courtesy of an announcement from the company regarding trilaciclib, its investigational therapy for bone marrow preservation.

News for G1 Therapeutics Stock (GTHX)